Henry Schein, Inc. $HSIC Shares Bought by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. has increased its stake in Henry Schein, Inc. by 14.7% during the third quarter, now owning 104,740 shares worth approximately $6.95 million. Other institutional investors have also adjusted their holdings, with 96.62% of the stock owned by hedge funds and institutional investors. Analysts have issued varied ratings, with a consensus "Hold" and an average target price of $76.42 for HSIC.
Henry Schein Inc. stock outperforms competitors on strong trading day
Henry Schein Inc. (HSIC) saw its stock advance by 3.61% to $79.57 on Friday, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average. Despite the strong performance, the company's stock closed 3.90% below its 52-week high. The article highlights HSIC's positive trading session in the context of a generally rising market.
Dentsply Sirona stock rating upgraded to buy by BofA on valuation
BofA Securities upgraded Dentsply Sirona (NASDAQ:XRAY) stock from Neutral to Buy, raising its price target to $17 from $13 due to perceived undervaluation and a positive risk/reward profile. The upgrade is based on BofA's expectation that the dental equipment maker's valuation gap with peers will narrow in 2026, driven by new management's progress in distributor relationships and potential multiple expansion. The firm also noted recent significant developments including renewed distribution agreements and leadership appointments.
Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry
Henry Schein One has launched Image Verify, an AI-driven tool for its Dentrix and Dentrix Ascend dental practice management systems. This new feature assesses the quality of clinical images in real time during capture, aiming to reduce claim denials caused by poor image quality. The company states that Image Verify is part of a broader initiative to streamline revenue cycle management and help dental practices achieve "clean claims," leading to faster reimbursements and reduced administrative work.
Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry
Henry Schein One has launched Image Verify, an AI-driven tool embedded in Dentrix and Dentrix Ascend, designed to enhance image quality control at the point of capture for dental practices. This innovation aims to reduce claim denials, which currently affect up to 20% of dental claims and contribute to significant revenue loss. Image Verify helps ensure diagnostic images are clear and high quality, minimizing retakes and accelerating reimbursement for practices.
Henry Schein One AI tool tackles dental claim denials topping 20%
Henry Schein One has launched AI-driven Image Verify, a new tool embedded in its Dentrix and Dentrix Ascend systems, designed to reduce dental claim denials. This innovation assesses image quality in real time during capture, addressing a leading cause of denials, as up to 20% of dental claims are initially denied, contributing to an average 9% annual revenue loss for practices. Image Verify aims to streamline the revenue cycle management process, enabling practices to submit cleaner claims and accelerate reimbursement.
Henry Schein One Launches Image Verify, Another Transformative Step Towards Achieving the Cleanest Claims in the Industry
Henry Schein One has launched Image Verify, an AI-driven tool embedded in Dentrix and Dentrix Ascend, designed to improve the quality of dental claims by verifying clinical images at the point of capture. This innovation aims to reduce claim denials, which currently cause significant revenue loss for dental practices, by preventing issues like blur and misalignment in images. Image Verify is part of Henry Schein One's broader mission to optimize revenue cycle management in dentistry, enabling practices to submit cleaner claims and accelerate reimbursement.
Thrivent Financial for Lutherans Sells 60,960 Shares of Henry Schein, Inc. $HSIC
Thrivent Financial for Lutherans significantly reduced its stake in Henry Schein, Inc. (NASDAQ:HSIC) by selling 60,960 shares in the third quarter, decreasing its holdings by 89.6% to 7,083 shares valued at approximately $470,000. Despite this, other institutional investors have either established new positions or increased their existing ones. Analyst sentiment for Henry Schein is mixed, with an average "Hold" rating and a price target of $76.42, although some analysts have upgraded their targets.
Europe Diagnostic Imaging Market is expected to reach US$ 12.32
The Europe Diagnostic Imaging Market is projected to grow from US$ 7.6 billion in 2023 to US$ 12.32 billion by 2031, exhibiting a CAGR of 6.2%. This growth is attributed to rising chronic diseases, aging populations, technological advancements, and a demand for early medical diagnosis. Key players in this market include Siemens Healthineers AG, GE Healthcare, Hitachi Medical Corporation, Hologic Inc., and Philips Healthcare.
Henry Schein (HSIC) Earnings Expected to Grow: Should You Buy?
Henry Schein (HSIC) is expected to report increased earnings and revenues for the quarter ended December 2025. While analysts project a 9.2% year-over-year EPS growth to $1.30 per share and revenues of $3.33 billion, the company's Zacks Earnings ESP of -0.77% combined with a Zacks Rank #3 makes it difficult to definitively predict an earnings beat. Despite a positive surprise history in past quarters, investors are advised to consider other factors beyond just earnings expectations.
Henry Schein One Integrates iTero Scanners
Henry Schein One has announced a direct data integration between Align Technology's iTero™ intraoral scanners and its practice management platforms: Dentrix, Dentrix Ascend, and Dentally. This collaboration aims to streamline digital scanning, diagnosis, and daily operations for dental practices globally by automatically importing iTero scans into patient records, eliminating manual steps. The integration enhances clinical confidence and operational efficiency, allowing dental teams to focus more on patient care and less on managing technology.
Zahn Dental Launches Zirlux Independence ML
Zahn Dental, a division of Henry Schein, Inc., has introduced Zirlux Independence ML, new multi-layered zirconia discs manufactured in the USA. These discs are designed to meet dental laboratories' demand for strength, superior esthetics, and efficiency, featuring consistent shades, natural multilayer esthetics, and full-disc milling capabilities. The product aims to streamline the milling process, improve production, and increase profitability for dental labs with its balance of strength and esthetics.
Henry Schein Q4 Earnings Preview: What's in Store for the Stock?
Henry Schein (HSIC) is set to release its fourth-quarter 2025 results on February 24, with analysts projecting revenue growth of 4.5% and EPS improvement of 9.2%. The company's performance is expected to be driven by strong sales in its Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments. While estimates for EPS have remained constant, the company currently holds a Zacks Rank #3 with an Earnings ESP of -0.77%.
Henry Schein One Connects Align Technology’s iTero Scanners to Dentrix, Dentrix Ascend, and Dentally, Advancing a More Connected Global Standard of Care
Henry Schein One announced a direct data integration between Align Technology’s iTero intraoral scanners and its practice management platforms: Dentrix, Dentrix Ascend, and Dentally. This integration automates the import of iTero scans into patient records, enhancing clinical workflows and operational efficiency for dental practices globally. The collaboration aims to provide immediate diagnostic insights and streamline the move from scanning to patient care within a single, connected environment.
Henry Schein's Integration Enhances Dental Efficiency
Henry Schein's integration of iTero scanners with its dental platforms dramatically improves efficiency by automating the import of 3D scans into patient records, eliminating manual tasks. This integration enhances clinical decision-making by providing immediate diagnostic insights and supports global dental practices across multiple countries, expanding Henry Schein's reach. The use of high-resolution 3D imaging technology is expected to drive the digital transformation of the dental industry, improving patient care and treatment outcomes.
Henry Schein One Connects Align Technology’s iTero™ Scanners to Dentrix, Dentrix Ascend, and Dentally, Advancing a More Connected Global Standard of Care
Henry Schein One has announced a new direct data integration connecting Align Technology's iTero™ intraoral scanners with its Dentrix, Dentrix Ascend, and Dentally practice management platforms. This integration streamlines workflows by automatically importing iTero scans into patient records, aiming to enhance diagnostic insights, operational efficiency, and care coordination for dental practices globally. The collaboration, which included Heartland Dental for its initial program, seeks to create a more connected standard of care in digital dentistry.
Dental scans flow into charts as Henry Schein One links iTero, Dentrix
Henry Schein One has announced the integration of Align Technology's iTero™ intraoral scanners with its practice management platforms: Dentrix, Dentrix Ascend, and Dentally. This new integration allows for the automatic import of iTero scans directly into patient records, enhancing clinical workflows, improving efficiency, and supporting better decision-making for dental professionals worldwide. The collaboration aims to create a more connected global standard of care in dentistry.
Henry Schein (HSIC) Expected to Announce Earnings on Tuesday
Henry Schein (NASDAQ:HSIC) is scheduled to release its Q4 2025 earnings before market open on February 24, 2026. Analysts anticipate an EPS of $1.30 and revenue of $3.3446 billion. The stock, currently trading down 0.3% at $78.19, has a market capitalization of $9.20 billion, and institutional investors own approximately 96.62% of its shares.
Henry Schein Shares: Expert Forecasts and Evaluations
Henry Schein, Inc. (HSIC) has underperformed the broader market, with investor concerns stemming from a lack of organic revenue growth and a declining free cash flow margin. Despite a recent dip following a CEO change, analysts predict a 3.6% increase in EPS for fiscal year 2025, with a consensus "Moderate Buy" rating and a highest price target of $90.
Henry Schein Shares: Expert Forecasts and Evaluations
Henry Schein, Inc. (HSIC) provides healthcare products to dental and medical professionals, with its shares underperforming the broader market despite modest gains in 2026. Investor concerns include a lack of organic revenue growth, declining free cash flow margins, and a recent stock drop following a CEO change. Analysts, however, project a 3.6% increase in EPS for fiscal year 2025 and maintain a "Moderate Buy" consensus rating, with an average price target of $78.14.
Henry Schein Stock: Analyst Estimates & Ratings
Henry Schein, Inc. (HSIC) is a healthcare products and services provider with a market capitalization of $9.2 billion. The company's stock has underperformed the broader market and the healthcare sector ETF over the past year, showing marginal growth. Analysts forecast a 3.6% YoY EPS growth for 2025, with a "Moderate Buy" consensus rating, although the mean price target sits below current market prices.
Henry Schein Stock: Analyst Estimates & Ratings
Henry Schein, Inc. (HSIC) has underperformed the broader market and healthcare ETFs over the past year, showing marginal growth. Analysts anticipate a 3.6% YoY EPS growth for 2025, with a "Moderate Buy" consensus based on varied ratings, and the stock's mean price target is currently below its market price. The company faces challenges like flat organic revenue growth and a decline in free cash flow margin, recently experiencing a stock dip after announcing a CEO transition.
Henry Schein Shares: Expert Forecasts and Evaluations
Henry Schein, Inc. (HSIC) provides healthcare products globally. Its shares have underperformed the broader market, with investor concerns arising from a lack of organic revenue growth and a declining free cash flow margin. Analysts project modest EPS growth for 2025, with a "Moderate Buy" consensus rating, but the average price target is below the current trading price.
Henry Schein, Inc. $HSIC Shares Acquired by Illinois Municipal Retirement Fund
The Illinois Municipal Retirement Fund increased its stake in Henry Schein, Inc. by 26.0% in the third quarter, acquiring an additional 19,316 shares. Other institutional investors like Ameriprise Financial Inc., Norges Bank, and M.D. Sass LLC also significantly boosted their holdings, bringing total institutional ownership to 96.62%. Analysts currently rate HSIC as a "Hold" with an average price target of $76.42, while the stock trades near $78.19.
Principal Financial Group Inc. Sells 20,618 Shares of Henry Schein, Inc. $HSIC
Principal Financial Group Inc. reduced its stake in Henry Schein, Inc. by 15.2% during the third quarter, selling 20,618 shares and now owning 115,145 shares valued at $7.64 million. Despite other hedge funds increasing their positions, analysts currently hold a "Hold" consensus rating for HSIC, with a target price of $76.42. The stock is trading near analyst targets with a market cap of $9.2 billion.
Interoperability woes still plague healthcare in 2026. Here's what to do about it.
Healthcare continues to struggle with interoperability in 2026, posing significant challenges for implementing new technologies like AI and achieving a holistic view of patient care. Experts suggest strategies to overcome these issues, including improving data quality at the source, connecting to health information exchanges (HIEs), and widely adopting industry standards such as FHIR and USCDI. These efforts aim to bridge data silos, enhance data access for clinicians, and ensure that technological advancements benefit all communities, not just the affluent.
Dental Impression Systems Market Size, Share | Forecast [2034]
The global dental impression systems market, valued at USD 1.85 billion in 2025, is projected to reach USD 3.30 billion by 2034, growing at a CAGR of 6.7%. This growth is driven by increasing demand for dental treatments, technological advancements, and a significant shift from traditional to digital impression systems. Key market players like Dentsply Sirona and Align Technology are focusing on innovation and strategic partnerships to capitalize on these opportunities.
Henry Schein Celebrates New Dallas Facility
Henry Schein is opening a new 8,300-square-foot Dallas Discovery Center in Southlake, Texas, on March 4, 2026. This facility will serve as a collaborative hub for dental and medical equipment, training, and innovation, bridging the gap between oral and overall health. The center will offer healthcare professionals a hands-on environment to explore advancements and enhance patient care.
Assessing Henry Schein (HSIC) Valuation As Growth And Returns Face Competitive Pressure
Henry Schein (HSIC) is facing competitive pressures, with its organic revenue growth and returns on capital shrinking. Despite a "most popular narrative" suggesting it's 2% overvalued at $79.72 against a fair value of $78.14, its P/E ratio at 24x earnings indicates it trades above the US Healthcare group but below its own fair ratio and peer average. The article encourages investors to analyze their own assumptions and offers tools to build a custom view of the company.
Henry Schein stock hits 52-week high, reaching 80.66 USD
Henry Schein (HSIC) stock has reached a 52-week high of $80.66 USD, currently trading at $81.03, just below its peak of $82.38. This surge is supported by aggressive share buybacks by management and investor confidence in its business model, despite a slight 1-year decline. Upcoming earnings on February 24, new CEO appointment, and strategic distribution agreements are key factors for investors to watch.
Henry Schein stock hits 52-week high, reaching 80.66 USD By Investing.com
Henry Schein Inc. (HSIC) stock has hit a 52-week high of $80.66, with its current price at $81.03, just below its peak. The company, with a market capitalization of $9.47 billion and a "GOOD" financial health rating, has shown resilience and investor confidence. Upcoming earnings on February 24, a new distribution agreement, and a new CEO appointment are key recent developments.
Henry Schein stock hits 52-week high, reaching 80.66 USD By Investing.com
Henry Schein Inc. (HSIC) stock has hit a 52-week high of $80.66, with current trading at $81.03, showing strong momentum with a 16.11% gain over the past six months, even after a slight 1-year decline. The company's financial health is rated “GOOD” by InvestingPro, indicating investor confidence despite trading above its Fair Value. Recent developments include a new distribution agreement with CytoChip Inc. for the CitoCBC system and the appointment of Frederick M. Lowery as the new CEO starting March 2026.
Henry Schein stock hits 52-week high, reaching 80.66 USD By Investing.com
Henry Schein Inc. (HSIC) stock recently reached a new 52-week high of $80.66, with its current price at $81.03. The company has shown strong momentum with a 16.11% gain over the past six months, driven partly by aggressive share buybacks and investor confidence. Key upcoming events for investors include an earnings report on February 24 and recent strategic moves such as a new distribution agreement and a CEO appointment.
Henry Schein stock hits 52-week high, reaching 80.66 USD By Investing.com
Henry Schein Inc. (HSIC) stock reached a 52-week high of $80.66 USD, currently trading at $81.03. Despite a slight 3.57% decline over the past year, the company has seen a 16.11% gain in the last six months, supported by aggressive share buybacks and strong investor confidence. Upcoming earnings on February 24, along with recent strategic moves like a new distribution agreement with CytoChip Inc. and the appointment of a new CEO, Frederick M. Lowery, are key points of interest for investors.
Free dental care drive aims to reach 325,000 U.S. children in 2026
The American Dental Association Foundation (ADAF) is kicking off its 2026 Give Kids A Smile (GKAS) program, aiming to provide free oral health education, screenings, cleanings, and restorative services to an estimated 325,000 underserved children across the U.S. The program, now in its 24th year, relies on 23,000 volunteers and 1,200 events nationwide. Long-time sponsors Henry Schein and Colgate-Palmolive continue to support the initiative, contributing products, resources, and educational programs to enhance children's oral health and overall well-being.
A Legacy of Brighter Smiles: Celebrating 24 Years of the Give Kids A Smile Program
The American Dental Association Foundation's Give Kids A Smile (GKAS) program is celebrating its 24th year, having provided essential dental services to over 10.2 million underserved children since 2003. Kicking off nationally in February for National Children's Dental Health Month, the program aims to reach 325,000 children in 2026 through 1,200 events and 23,000 volunteers. Longtime sponsors Henry Schein and Colgate-Palmolive continue to provide crucial support through product donations and oral health education initiatives.
Dental Equipment Market is expected to reach US$ 12.4 billion
The global Dental Equipment Market is projected to grow from US$ 6.8 billion in 2024 to US$ 12.4 billion by 2033, exhibiting a CAGR of 7.0%. This growth is driven by increasing oral health awareness, technological advancements, demand for cosmetic dentistry, and improvements in dental care infrastructure. Key players in this market include Henry Schein, Dentsply Sirona, and 3M.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and Azenta (AZTA)
Analysts have issued neutral ratings for healthcare companies Henry Schein (HSIC) and Azenta (AZTA), indicating neither a bullish nor bearish stance. William Blair's Brandon Vazquez maintained a Hold rating on Henry Schein, while TD Cowen's Brendan Smith also maintained a Hold rating on Azenta, setting a price target of $30.00. Both companies currently hold a Moderate Buy consensus from analysts, with respective average price target upsides of 8.5% for Henry Schein and 25.8% for Azenta.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and Azenta (AZTA)
Analysts have issued neutral ratings for healthcare companies Henry Schein (HSIC) and Azenta (AZTA), indicating neither a bullish nor bearish outlook. William Blair maintained a Hold rating on Henry Schein with an average price target of $79.75, while TD Cowen maintained a Hold rating on Azenta with a price target of $30.00. Both companies currently hold a Moderate Buy consensus among analysts.
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and Azenta (AZTA)
Analysts have issued neutral "Hold" ratings for healthcare companies Henry Schein (HSIC) and Azenta (AZTA), suggesting they are neither bullish nor bearish on the stocks. William Blair analyst Brandon Vazquez maintained a Hold on Henry Schein with an average price target indicating an 8.5% upside, while TD Cowen analyst Brendan Smith maintained a Hold on Azenta, setting a price target suggesting a 25.8% upside.
Dental sector may steady in 2026, but full recovery remains distant, analysts say
Analysts are cautiously optimistic that the dental sector will stabilize in 2026 after a volatile 2025, but they warn that a full recovery is still far off. While there are signs of improvement in patient volumes and clear aligner demand, factors like elevated prices, labor market anxiety, and shifting consumer sentiment continue to suppress discretionary dental care. Major dental product manufacturers like Henry Schein, Align Technology, Envista, and Dentsply Sirona faced challenges in 2025, leading analysts to anticipate conservative forecasts for the coming year.
Align Technology Taps Swiss Oral Health Study To Deepen Digital Dentistry Roots
Align Technology is collaborating with the University of Bern on Switzerland's first nationwide oral health study, providing its iTero Lumina intraoral scanner and diagnostic tools. This partnership integrates Align's digital dentistry into public health research, highlighting the growing role of digital diagnostics in oral care and aiming to deepen relationships with clinicians and policymakers in a key European market. For investors, this move suggests long-term adoption potential for Align's digital workflow beyond orthodontics, amidst competition from other dental technology providers.
Envista (NVST) To Report Earnings Tomorrow: Here Is What To Expect
Envista Holdings (NVST) is set to report earnings, with analysts expecting revenue growth of 4% year-on-year to $678.7 million and adjusted earnings of $0.32 per share. The company has a history of beating revenue expectations but has also missed Wall Street's estimates twice in the last two years. While the healthcare equipment segment has seen minor stock price declines, Envista's shares are up 1.6% in the last month.
Henry Schein (BIT:1HSIC) Price Target Decreased by 12.37% to 65.12
Fintel reports that the average one-year price target for Henry Schein (BIT:1HSIC) has been decreased by 12.37% to €65.12 per share, down from €74.31. This revised target still represents an increase of 12.43% from the latest closing price of €57.92. Despite a decrease in the number of institutional owners, major shareholders like Kohlberg Kravis Roberts & Co. and Artisan Partners Limited Partnership continue to hold significant positions.
New Akso Health program offers zero-cost cancer care for up to 10,000 patients
Akso Health Group announced an exploratory global patient support initiative and a strategic cooperation with Nanning Duoling Research Institute to provide free in-hospital treatment plans for up to 10,000 eligible cancer patients. The program integrates Traditional Chinese Medicine practice with modern medical technology, connecting radiation oncology centers, targeted drugs, and remote consultation teams. While aiming to address high medical costs and accessibility, the initiative is exploratory, conditional, and services will be delivered by independent medical institutions, not directly by Akso Health.
Assessing Henry Schein’s Valuation After Greenlight Capital’s Push For Operational Improvements
The article discusses the valuation of Henry Schein (HSIC) following Greenlight Capital's new position, advocacy for activist board additions, upcoming CEO transition, and focus on cost discipline and e-commerce. Henry Schein is currently trading near analyst targets with a narrative suggesting it is 3.4% undervalued, primarily due to strong growth in high-margin segments and investments in digital transformation. However, the valuation depends on successful execution amidst competitive pricing and leadership changes.
How Henry Schein Inc. (HSIC) Affects Rotational Strategy Timing
This article analyzes Henry Schein Inc. (HSIC) using AI models to suggest trading strategies based on different risk profiles. It identifies a weak near-term sentiment for HSIC, presenting a significant risk-reward short setup. The analysis provides specific entry, target, and stop loss points for position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
Does Henry Schein (HSIC) Have Potential for Margin Improvement and Increased Shareholder Value?
Greenlight Capital, an investment management company, recently highlighted Henry Schein, Inc. (NASDAQ:HSIC) as a new holding in its fourth-quarter 2025 investor letter. The firm believes that cost inefficiencies leading to margin erosion will be addressed by new board members and a pending CEO change, which could lead to significant free cash flow generation and share buybacks. Henry Schein, Inc. is a leading distributor of dental and medical products, and Greenlight Capital purchased its shares at an average price of $68.11, with the stock closing at $75.58 at the end of the quarter.
Henry Schein, Inc. $HSIC Holdings Lowered by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 24.7% in the third quarter. Despite this reduction, other large institutions like Ameriprise, Norges Bank, and Bank of America increased or initiated substantial positions, maintaining institutional ownership at 96.62%. The company recently beat Q3 EPS expectations and provided FY2025 guidance, while analysts currently rate the stock as a "Hold" with an average price target of $76.42.
Vanguard Personalized Indexing Management LLC Has $7.03 Million Position in ITT Inc. $ITT
Vanguard Personalized Indexing Management LLC increased its stake in ITT Inc. by 18.2% in the third quarter, now owning 39,325 shares valued at approximately $7.03 million. Other hedge funds have also adjusted their positions in ITT, which reported strong Q3 earnings, beating analyst expectations. Despite positive analyst ratings and financial performance, company insiders have recently sold shares.
